Journal article
A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma
Greg Hapgood, Janey M Stone, Diana Zannino, Anup George, Paula Marlton, Henry Miles Prince, Chi-Hung Hui, Ian Prosser, Ian D Lewis, Kenneth Bradstock, John F Seymour
Leukemia & Lymphoma | TAYLOR & FRANCIS LTD | Published : 2019
Grants
Funding Acknowledgements
This work was supported by grants from Amgen Australia and Mayne Pharma.